PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE

Samankaltaisia teoksia

• Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
  Tekijä: Ajay K. Nooka, et al.
  Julkaistu: (2022-04-01)
• EVALUATION OF DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (D-VRD) INDUCTION FOLLOWED BY DARATUMUMAB AND LENALIDOMIDE (DR) MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS IN BRAZIL
  Tekijä: JTD Souto-Filho, et al.
  Julkaistu: (2024-10-01)
• REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
  Tekijä: EQ Crusoe, et al.
  Julkaistu: (2024-10-01)
• Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
  Tekijä: Dong Liang, et al.
  Julkaistu: (2024-09-01)
• Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
  Tekijä: Yin-Che Wang, et al.
  Julkaistu: (2025-12-01)